Jinwu Financial News | Federal Pharmaceuticals (03933) announced that in 2023, company owners should account for the current year's profit of RMB 2,701 billion (RMB, same below), up 70.9% year on year; basic profit per share was 148.67 points, up 71.1% year on year; the board of directors proposed to pay a final dividend of RMB 28 points per share for the year ended December 31, 2023, and a special dividend of RMB 12 points per share. Together with the interim dividend of RMB 12 per share already paid, the annual dividend is RMB 52 cents per share.
During the period, the company achieved revenue of 13.74 billion yuan, up 21.2% year on year; gross profit of 6.335 billion yuan, up 27.49% year on year.
This year, the Group invested 808 million yuan in R&D, an increase of 36.2% over the previous year.
During the year, the intermediates and APIs separately recorded foreign sales revenue of approximately $2,317 billion and $6.399 billion, up 44.9% and 23.7% year-on-year respectively. Market prices for intermediates and APIs are gradually rising, driven by a recovery in demand represented by overseas markets. Overseas exports recorded sales revenue of 2,616 billion yuan, up 10.3% year on year, accounting for 19.0% of the Group's total sales. The Group continues to occupy a leading position in the domestic and export markets for intermediates and APIs.
During the year, foreign sales revenue of pharmaceutical products was about 5,024 billion yuan, an increase of 10.2% over the previous year.